Browse > Article
http://dx.doi.org/10.6564/JKMRS.2022.26.3.034

Molecular interaction between SH3 domain of PACSIN2 and proline-rich motifs of Cobll1  

Yoo, Hee-Seop (Department of Molecular Science and Technology, Ajou University)
Seok, Seung-Hyeon (College of Pharmacy and Interdisciplinary Graduate Program in Advanced Convergence Technology & Science, Jeju National University)
Kim, Ha-Neul (Department of Molecular Science and Technology, Ajou University)
Kim, Ji-Hun (College of Pharmacy, Chungbuk National University)
Seo, Min-Duk (Department of Molecular Science and Technology, Ajou University)
Publication Information
Journal of the Korean Magnetic Resonance Society / v.26, no.3, 2022 , pp. 34-39 More about this Journal
Abstract
The SH3 domain found within a variety of proteins is comprised of generally 60 residues, and participated in protein-protein interactions with proline-rich motifs. Cobll1 was identified as a distinct molecular marker associated with CML progression, and PACSIN2 was discovered a novel Cobll1 binding partner through direct interaction between a SH3 domain of PACSIN2 and three proline-rich motifs of Cobll1. To understand the structural basis of interactions between PACSIN2 and Cobll1, backbone assignments of PACSIN2 SH3 domain were performed. Furthermore, three proline-rich peptides of Cobll1 were titrated to 15N-labeled PACSIN2 SH3 domain in various ratios. Our chemical shift changes data and conserved SH3 sequence alignment will be helpful to analyze fundamental molecular basis related to the interaction between PACSIN2 and Cobll1.
Keywords
Cobll1; PACSIN2; proline-rich motif; SH3 domain; chronic myeloid Leukemia;
Citations & Related Records
연도 인용수 순위
  • Reference
1 B. Chereda and J. V. Melo, Ann. Hematol. 94, (2015)
2 T. Nagase, K. Ishikawa, M. Suyama, R. Kikuno, M. Hirosawa, N. Miyajima, A. Tanaka, H. Kotani, N. Nomura, O. Ohara, DNA Res. 6, 1 (1999)   DOI
3 P. Hana, J. Pavlina, M. Archana, S. Lucie, P. Lucie, L. Antonin, P. Karla, O. Petra, R. Lenka, D. Michael, P. Sarka, P. Sarka and B. Vitezslav, Haematologica 103, 2 (2018)
4 U. Przemyslaw, M. Damian, C. Michal, S. Krzysztof, T. Maciej, D. Violetta and P. Andrzej, Biomedicines 10, 8 (2022)
5 S. H. Han, S. K. Kim, H. J. Kim, Y. Lee, S. Y. Choi, G. Park, D. H. Kim, A. Lee, J. Kim, J. M. Choi, Y. Kim, K. Myung, H. Kim and D. W. Kim, Leukemia 31, 7 (2017)
6 S. M. Tsveta, A. U. Ana, N. Julian, T. Marina, M. S. Miesje, J. Vera, H. Annett, G. G. Anouk, T. Merel, G. Mariona, P. Markus and H. Stephan, Nat. Commun. 12, 2610 (2021)   DOI
7 K. B. Park, H. S. Yoo, C. K. Oh, J. R. Lee, H. J. Chung, H. N. Kim, S. H. Kim, K. M. Kee, T. Y. Kim, M. S. Kim, B. H. Kim, J. S. Ra, K. J. Myung, H. T. Kim, S. H. Han, M. D. Seo, Y. S. Lee, D. W. Kim, Cancer Med. 10, 1002 (2022)
8 J. Elias, Am. J. Hematol. 91, 1 (2016)   DOI
9 J. D. Brian, G. Francois, G. O. Stephen, G. Insa and A. L. Richard et al., N. Engl. J. Med. 355, (2006)
10 T. Kenichi, S. Takashi, F. Tetsuya and I. Satoshi, Proc. Natl. Acad. Sci. U.S.A. 115, 19 (2018)   DOI
11 B. Ritter, J. Modregger, M. Paulsson and M. Plomann, FEBS Lett. 454, 3, (1999)
12 N. Kurochkina and U. Guha, Biophys Rev. 5, 1 (2012)
13 A. E. Christopher, O. Thomas, Curr. Hematol. Malig. Rep. 10, 2 (2015)
14 F. Stefan, T. Moshe, E. Zeev, O. Susan, K. Razelle, and M. K. Hagop, N. Engl. J. Med. 341, (1999)
15 C. Bruno and P. Danilo, Blood 103, 11 (2004)   DOI
16 P. S. Neil, T. Chris, Y. L. Francis, C. Ping, N. Derek and L. S. Charles, Science 305, 5682 (2004)